Financial Performance - Operating revenue for the reporting period was ¥890,917,081.32, reflecting an increase of 11.48% year-on-year[3]. - Net profit attributable to shareholders was ¥211,987,262.90, representing an 8.06% increase compared to the same period last year[3]. - Basic earnings per share were ¥0.24, up by 9.09% year-on-year[3]. - The net profit for the third quarter of 2019 was CNY 211,987,262.90, an increase from CNY 196,173,056.94 in the same period last year, representing a growth of approximately 8.8%[28]. - The total profit for the quarter was CNY 256,245,391.08, compared to CNY 226,652,796.14 in the previous year, marking an increase of about 13.1%[28]. - Net profit for the current period was ¥552,269,121.81, representing an increase of 9.06% from ¥506,456,695.84 in the previous period[36]. - Basic and diluted earnings per share increased to ¥0.63 from ¥0.58, marking a growth of 8.62%[37]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,507,893,053.46, an increase of 6.03% compared to the end of the previous year[3]. - The company's current assets totaled CNY 3,087,387,024.62, down from CNY 3,412,828,931.88 in the previous year, indicating a decrease of approximately 9.5%[20]. - Total liabilities decreased to CNY 1,052,528,035.25 from CNY 1,110,927,768.65, indicating a decline of approximately 5.2%[21]. - The company's total liabilities were reported at ¥306,224,337.93, a decrease from ¥327,773,747.60 in the previous year[25]. - The total non-current assets increased to CNY 2,420,506,028.84 from CNY 1,782,053,325.47, marking an increase of approximately 35.9%[20]. - The company reported a total of CNY 588,450,297.30 in current liabilities, a decrease from CNY 619,968,077.61, indicating a reduction of about 5.1%[21]. Cash Flow - The net cash flow from operating activities surged by 354.51% to ¥298,508,259.17 during the reporting period[3]. - Net cash flow from operating activities increased by 161.73% year-on-year, mainly due to an increase in sales receipts during the reporting period[11]. - Cash inflow from operating activities reached CNY 2,642,901,847.60, up from CNY 2,213,931,344.10 in the prior period, reflecting a growth of approximately 19.4%[43]. - The net cash flow from operating activities was CNY 537,694,549.68, significantly higher than CNY 205,437,457.68 in the previous year, marking an increase of about 161.5%[43]. - The cash flow from investment activities resulted in a net outflow of CNY 789,780,131.01, an improvement from the previous net outflow of CNY 1,163,528,865.95[44]. - The net cash flow from financing activities was negative CNY 229,186,018.41, worsening from a negative CNY 193,507,731.14 in the previous period[44]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,461[6]. - The largest shareholder, Chengdu Kanghong Technology Industry (Group) Co., Ltd., held 33.35% of the shares[6]. - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[7]. Expenses - Operating expenses increased by 102.04% year-on-year, mainly due to an increase in charitable donations during the reporting period[10]. - Financial expenses increased by 37.08% compared to the same period last year, mainly due to a decrease in interest income and exchange rate fluctuations[10]. - Research and development expenses increased to ¥87,574,093.66, compared to ¥63,778,560.19 in the previous year, marking a growth of 37.3%[27]. - The company's sales expenses were ¥1,191,589,949.37, slightly up from ¥1,136,025,229.00, reflecting a 4.91% increase[35]. Government Support - The company received government subsidies amounting to ¥59,215,778.81 during the reporting period[4]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[36].

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 1,518,730,676.02, representing a 9.79% increase compared to CNY 1,383,304,018.51 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was CNY 340,281,858.91, up 9.67% from CNY 310,283,638.90 in the previous year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 315,756,728.11, reflecting an 18.07% increase from CNY 267,430,611.58 in the same period last year[11]. - The net cash flow from operating activities was CNY 239,186,290.51, a significant increase of 71.14% compared to CNY 139,760,397.27 in the previous year[11]. - The basic earnings per share were CNY 0.39, an increase of 8.33% from CNY 0.36 in the same period last year[11]. - The diluted earnings per share were CNY 0.39, up 11.43% from CNY 0.35 in the previous year[11]. - The total assets at the end of the reporting period were CNY 5,188,615,792.52, a slight decrease of 0.12% from CNY 5,194,882,257.35 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company increased by 3.82% to CNY 4,239,875,843.70 from CNY 4,083,954,488.70 at the end of the previous year[11]. Investment and R&D - R&D investment surged by 125.73% to RMB 283,991,584.25, reflecting a significant increase in innovation efforts[25]. - The company has established a new drug research institute, product technology center, and medical research center to enhance its R&D capabilities in key therapeutic areas[21]. - The company is focusing on core therapeutic areas such as ophthalmology, neurology, oncology, and chronic disease prevention, with ongoing investments in high-quality new products[21]. - The company maintains a strong focus on four key technologies: macromolecular protein drug industrialization, standardized quality control for traditional Chinese medicine, new formulation technology for solid oral drugs, and green synthesis technology for chemical raw materials[16]. Market and Product Development - The company has a total of 12 marketed drugs and one medical device, with significant patent holdings, including 33 for its ophthalmic product[17]. - The company has completed the acquisition of 80% equity in IOPtima Ltd., expanding its ophthalmic product line and entering the ophthalmic device and consumables market[22]. - The company launched the third indication for its drug Conbercept, now approved for treating diabetic macular edema (DME)[23]. - The company’s international new drug candidates, including Conbercept, have received international patents in multiple countries, indicating significant future market potential[22]. Financial Management and Capital Structure - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[2]. - The company has a total of 190 authorized patents, including 79 foreign patents, emphasizing its commitment to intellectual property protection[23]. - The total number of shares increased from 673,536,680 to 875,597,684, representing a capital increase of RMB 673,536,680 through capital reserve conversion[96]. - The company repurchased and canceled 2,024,721 shares at a price of 22.5462 yuan per share, which is 0.2312% of the total share capital[99]. Environmental and Social Responsibility - The company is actively involved in social responsibility initiatives, contributing to public health and charitable causes[23]. - The company donated a total of 31.0168 million yuan to social welfare activities in the first half of 2019, covering provinces such as Sichuan, Jiangxi, Anhui, and Shandong[91]. - The company has provided free medical assistance valued at over 230 million yuan to impoverished patients across 30 provinces since the establishment of its public welfare fund in 2014[90]. - The company has established a public welfare fund to assist in medical poverty alleviation efforts in underdeveloped regions[90]. Compliance and Governance - The company has made commitments regarding shareholding and management practices, ensuring compliance with relevant regulations[49]. - The company has not experienced any major litigation or arbitration matters during the reporting period[55]. - The company has not undergone any bankruptcy restructuring during the reporting period[54]. - The financial report for the first half of 2019 was not audited[116]. Risk Management - The company anticipates ongoing risks related to declining sales prices due to national healthcare reforms and increased competition in the pharmaceutical market[47]. - The company faces risks associated with the implementation of fundraising projects, which may not meet expected revenue and profit targets due to market uncertainties[47]. - The company is addressing potential talent shortages as it expands its operations and business scope[47]. - The company has outlined measures to mitigate risks associated with project implementation and market conditions[47].

Financial Performance - The company's operating revenue for Q1 2019 was ¥717,015,649.78, representing a 2.43% increase compared to ¥699,991,074.72 in the same period last year[3]. - The net profit attributable to shareholders for Q1 2019 was ¥211,005,149.07, up by 2.44% from ¥205,986,366.58 year-on-year[3]. - The company's operating profit for Q1 2019 was CNY 252.59 million, an increase from CNY 246.12 million in the same period last year, representing a growth of approximately 2.0%[22]. - The total profit for Q1 2019 was CNY 251.03 million, compared to CNY 244.30 million in the same period last year, reflecting an increase of about 2.8%[22]. - The total comprehensive income for Q1 2019 was CNY 211.69 million, up from CNY 205.38 million in the previous year, indicating a growth of approximately 3.2%[23]. - The net profit for Q1 2019 reached CNY 211.01 million, compared to CNY 205.99 million in Q1 2018, reflecting a year-over-year increase of about 2.0%[22]. Cash Flow - The net cash flow from operating activities significantly increased by 530.08%, reaching ¥76,206,590.42 compared to ¥12,094,762.53 in the previous year[3]. - Cash flow from operating activities for Q1 2019 was CNY 713.80 million, compared to CNY 593.55 million in Q1 2018, representing an increase of about 20.3%[27]. - Total cash inflow from operating activities reached 726,022,369.93 CNY, compared to 602,747,444.02 CNY in the same period last year, indicating an increase of approximately 20.5%[28]. - Cash outflow from operating activities totaled 649,815,779.51 CNY, up from 590,652,681.49 CNY, representing an increase of about 10%[28]. - The net cash flow from investment activities was -723,810,507.24 CNY, an improvement from -923,484,508.58 CNY year-over-year[29]. - The cash and cash equivalents at the end of the period were 1,844,380,147.93 CNY, down from 2,187,139,204.48 CNY, reflecting a decrease of about 15.7%[29]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,345,864,760.65, a 2.91% increase from ¥5,194,882,257.35 at the end of the previous year[3]. - Total liabilities decreased to approximately ¥1.05 billion from ¥1.11 billion at the end of the previous year[15]. - Total assets reached approximately ¥5.35 billion, up from ¥5.19 billion at the end of the previous year[14]. - Total current assets were CNY 1,335,894,138.16, with cash and cash equivalents at CNY 1,059,726,925.70[35]. - Total liabilities reached CNY 1,110,927,768.65, with current liabilities at CNY 619,968,077.61[34]. Shareholder Information - The top ten shareholders held a combined 99.87% of the total shares, with Chengdu Kanghong Technology Industry (Group) Co., Ltd. holding 33.35%[6]. - The total equity attributable to shareholders of the parent company reached CNY 4,296,053,944.07, up from CNY 4,083,954,488.70, marking an increase of approximately 5.2%[18]. - Shareholders' equity totaled CNY 4,083,954,488.70, with undistributed profits of CNY 2,526,888,621.06[34]. Research and Development - Research and development expenses rose by 43.09% year-on-year, attributed to increased R&D investment[10]. - Research and development expenses increased to CNY 46,433,584.24 in Q1 2019, compared to CNY 32,449,971.93 in the previous year, reflecting a significant increase of approximately 43%[21]. - Research and development expenses increased to CNY 23.74 million in Q1 2019, up from CNY 13.83 million in the same period last year, marking a significant increase of approximately 71.8%[24]. Other Financial Metrics - The weighted average return on net assets was 5.04%, a decrease of 0.61% from the previous year[3]. - The basic earnings per share remained stable at ¥0.31, while diluted earnings per share increased by 3.33% to ¥0.31[3]. - The company reported a significant decrease of 80.32% in financial expenses year-on-year, mainly due to exchange rate fluctuations[10]. - The company incurred income tax expenses of CNY 40.02 million in Q1 2019, up from CNY 38.32 million in Q1 2018, indicating an increase of approximately 4.4%[22]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance competitive positioning[21].

Financial Performance - The company's operating revenue for 2018 was ¥2,917,445,131.66, representing a 4.70% increase compared to ¥2,786,497,000.62 in 2017[11]. - The net profit attributable to shareholders for 2018 was ¥694,943,801.74, an increase of 7.88% from ¥644,199,027.01 in 2017[11]. - The company reported a basic earnings per share of ¥1.04 for 2018, up 8.33% from ¥0.96 in 2017[11]. - The revenue from chemical drugs was CNY 1,169,995,125.14, showing an increase of 8.02% year-on-year[31]. - The revenue from biological products reached CNY 882,090,768.08, with a significant growth of 42.79% compared to the previous year[31]. - The company’s traditional Chinese medicine revenue decreased by 20.40% to CNY 863,378,989.41[31]. - The total revenue from the pharmaceutical industry amounted to 227,818,268.62 CNY in 2018, a decrease of 15.17% from 268,546,852.93 CNY in 2017[35]. - The company achieved a total operating revenue of CNY 2,917,445,131.66 in 2018, representing a year-on-year growth of 4.70%[31]. - The company reported a total revenue of 1.5 billion CNY for the year 2018, representing a year-over-year growth of 20%[86]. - The net profit for 2018 was 300 million CNY, an increase of 15% compared to the previous year[86]. Dividend Distribution - The company reported a total profit distribution plan based on 673,536,680 shares, proposing a cash dividend of 2.80 RMB per 10 shares (tax included) and a capital reserve increase of 3 shares per 10 shares[1]. - The company plans to distribute a cash dividend of CNY 2.80 per 10 shares for the 2018 fiscal year, totaling CNY 188,590,270.40[81]. - The cash dividend for 2017 was CNY 2.80 per 10 shares, amounting to CNY 188,778,807.56, which represented 29.30% of the net profit attributable to shareholders[80]. - The cash dividend for 2016 was CNY 1.50 per 10 shares, totaling CNY 101,243,109.00, accounting for 20.38% of the net profit attributable to shareholders[80]. - The total distributable profit for 2018 was CNY 694,943,801.74, with the cash dividend representing 48.28% of this amount[81]. - The total cash dividend for 2018, including other methods, is CNY 188,590,270.40, which is 27.14% of the net profit attributable to shareholders[80]. - The company has maintained a consistent cash dividend policy over the past three years, with clear standards and procedures in place[81]. Research and Development - The company has established four key technologies in drug development, including large molecule protein drug industrialization technology and standardized quality control technology for traditional Chinese medicine[18]. - The company’s R&D investment has increased, with a focus on high-quality new products in ophthalmology, neurology, and oncology[24]. - The company has 57 ongoing research projects, including a new drug for diabetic macular edema that has completed clinical trials and is under review for market approval[41]. - The total amount of R&D investment was 348,861,949.84 CNY, representing 11.96% of the company's revenue in 2018, a decrease from 12.56% in 2017[43]. - Research and development expenses increased by 20.02% year-on-year, totaling 230,365,772.13 CNY in 2018 compared to 191,933,002.81 CNY in 2017[40]. - The company obtained 29 authorized patents during the reporting period, bringing the total to 203, including 99 foreign patents[29]. - The company has established a comprehensive technical system for new drug research, including a New Drug Research Institute and a Medical Research Center[69]. Market Expansion and Strategy - The company aims to enhance its market presence through continuous innovation and collaboration in the pharmaceutical sector[18]. - The company is expanding its market presence in response to intensified competition from multinational pharmaceutical companies entering the domestic market[68]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2020[86]. - The company is focused on expanding its marketing service network, although it faced challenges due to local purchase restrictions and fluctuations in housing prices[55]. - The sales strategy will be market-driven, with a focus on rapid market capture and refined marketing strategies, utilizing data analysis for better market insights[71]. - The company is exploring partnerships with international firms to enhance its global distribution network[186]. Risks and Challenges - The company faces risks including declining sales prices, challenges in drug development, implementation of fundraising projects, and talent shortages[1]. - The company faces risks including potential sales price declines due to healthcare reforms and increased competition in the pharmaceutical market[74]. - There is a significant investment in drug R&D, which carries risks of uncertainty and potential failure due to the lengthy and costly development process[74]. - The company faced delays in project progress due to design optimization and market conditions affecting the expansion of traditional Chinese medicine production lines[55]. Social Responsibility - The company actively participated in social responsibility initiatives, donating 44.23 million to various charitable causes in 2018[123]. - The company has established the "Langshijie Muguangming" fund to support medical precision poverty alleviation, benefiting impoverished areas with free medical services[122]. - The company organized 205 public health activities, including free health consultations and lectures, to promote community health awareness[123]. - The company has committed to integrating social responsibility into its business strategy, with a dedicated team led by the chairman[120]. - The company has provided free medical products worth over 200 million to impoverished patients since the establishment of its public welfare fund in 2014[122]. Environmental Compliance - The company is listed as a key pollutant discharge unit, with specific emissions monitored and reported[127]. - The company maintained compliance with environmental discharge standards, with no instances of exceeding pollutant limits reported[129]. - The company has implemented a pollution liability insurance policy as part of its environmental protection measures[151]. - The company has engaged in community environmental awareness activities, such as the "Kanghong Pharmaceutical and You Build a Happy Community" campaign[150]. Corporate Governance - The company has established a performance evaluation system linking remuneration to company performance and individual performance[191]. - The company operates independently from its controlling shareholder in terms of business, personnel, assets, institutions, and finance[199]. - The company has established a complete independent business structure and operates its own supply, production, and sales systems[199]. - The company has not reported any changes in its actual controller during the reporting period[173].

成都康弘药业集团股份有限公司 2018 年第三季度报告全文 成都康弘药业集团股份有限公司 2018 年第三季度报告 2018-075 2018 年 10 月 1 成都康弘药业集团股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证季度报告中财务报表的真实、准确、完整。 2 成都康弘药业集团股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 4,950,080,379.05 | 4,586,159,245.38 | | 7.94% | | 归属于上市公司股东的净 ...

成都康弘药业集团股份有限公司 2018 年半年度报告全文 成都康弘药业集团股份有限公司 2018 年半年度报告 2018-060 2018 年 08 月 1 成都康弘药业集团股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证本半年度报告中财务报告的真实、准确、完整。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 2018 | 年半年度报告 2 | | --- | --- | | 第一节 | 重要提示、释义 2 | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 公司业务概要 8 | | 第四节 | 经营情况讨论与分析 26 | | 第五节 | 重要事项 26 | | 第六节 | 股份变动及股东情况 43 | | 第七节 | 优先股相关情况 55 | | 第八节 | 董事、监事、高级管 ...

成都康弘药业集团股份有限公司 2017 年年度报告全文 成都康弘药业集团股份有限公司 2017 年年度报告 2018-018 2018 年 04 月 1 成都康弘药业集团股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1 、销售价格下降的风险 随着国家基本医疗保险制度改革的深入、相关 政策法规的调整或出台，我国药品降价的趋势仍将持续，尤其是随着卫生部门 药品网上招标采购、医疗保险对药费支付设置限制标准等政策的推进，公司产 品的销售价格可能会因此而降低；同时，医药产品市场竞争的进一步加剧，医 院药品招投标采购方式的进一步推广和变革，也可能导致本公司产品价格的下 降。 2、药品研发风险 公司基于未来发展所需，每年都必须投入大量资金 用于药品的研发。一种新药从实验研究、临 ...

成都康弘药业集团股份有限公司 2018 年第一季度报告正文 证券代码：002773 证券简称：康弘药业 公告编号：2018-024 成都康弘药业集团股份有限公司 2018 年第一季度报告正文 1 成都康弘药业集团股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证季度报告中财务报表的真实、准确、完整。 2 所有董事均已出席了审议本次季报的董事会会议。 √ 适用 □ 不适用 成都康弘药业集团股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 699,991,074.72 | 642,039,416.94 | 9.03% | ...

成都康弘药业集团股份有限公司 2017 年年度报告全文 成都康弘药业集团股份有限公司 2017 年年度报告 2018-018 1 成都康弘药业集团股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1 、销售价格下降的风险 随着国家基本医疗保险制度改革的深入、相关 政策法规的调整或出台，我国药品降价的趋势仍将持续，尤其是随着卫生部门 药品网上招标采购、医疗保险对药费支付设置限制标准等政策的推进，公司产 品的销售价格可能会因此而降低；同时，医药产品市场竞争的进一步加剧，医 院药品招投标采购方式的进一步推广和变革，也可能导致本公司产品价格的下 降。 2、药品研发风险 公司基于未来发展所需，每年都必须投入大量资金 用于药品的研发。一种新药从实验研究、临床试验、获得新药证书到正 ...

所有董事均已出席了审议本次季报的董事会会议。 成都康弘药业集团股份有限公司 2017 年第三季度报告全文 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明:保证季度报告中财务报表的真实、准确、完整。 成都康弘药业集团股份有限公司 2017 年第三季度报告 2017 年 10 月 l 成都康弘药业集团股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 2 成都康弘药业集团股份有限公司 2017年第三季度报告全文 | 项目 | 年初至报告期期末全额 | 说明 | | --- | --- | --- | | 非流动资产处置损益(包括已计提资产减值准备的冲销部分) | | -49,220.87 系固定资报废处置损失 | | 计入当期损益的政府补助(与企业业务密切相关,按照国家统 | 15,791,175.68 | 系当期收到及从递延收益转入 | | 标准定额或定量享受的政府补助除外) | | 的政府补助 | | 除上述 ...